文献速递心境障碍

双相II型抑郁急性期治疗:锂盐、舍曲林及联合治疗的转换率随机双盲比较

Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison.
PubMed 文献 · Am J Psychiatry · 2017-01-31

一项16周双盲多中心研究将142例双相II型抑郁患者随机分配至锂盐单药、舍曲林单药或锂盐联合舍曲林治疗,比较药物所致心境转换风险。结果显示三组转换率无显著差异,总转换率为14%,总体治疗应答率为62.7%,联合组脱落率更高且无加速应答优势。

要点

  • 锂盐单药、舍曲林单药及联合治疗在双相II型抑郁中的转换率和应答率相似。
  • 总转换率为14%,多数发生在治疗前5周,无躁狂转换或因转换住院。
  • 联合组脱落率显著高于单药组,且未加速治疗应答。

核心结论

  • 锂盐单药、舍曲林单药和锂盐联合舍曲林治疗双相II型抑郁的转换率和治疗应答率相似。
  • 联合治疗组脱落率更高,且无治疗加速优势。

研究设计与样本

  • 16周双盲多中心随机对照研究,纳入142例双相II型抑郁患者,随机分配至锂盐单药组(N=49)、舍曲林单药组(N=45)或锂盐联合舍曲林组(N=48)。

主要发现

  • 转换率在三组间无显著差异,即使考虑脱落因素后仍无差异。
  • 多数转换发生在治疗前5周内。
  • 总体治疗应答率为62.7%(N=89),考虑脱落因素后组间无显著差异。
  • 锂盐联合舍曲林组总体脱落率显著高于单药组,且未加速应答时间。

临床怎么用

  • 双相II型抑郁急性期可考虑锂盐单药或舍曲林单药,两者转换风险与应答率相似。
  • 锂盐联合舍曲林不降低转换风险且脱落率更高,不作为优先选择。
  • 治疗前5周需密切监测心境转换,尤其是轻躁狂症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The authors compared medication-induced mood switch risk (primary outcome), as well as treatment response and side effects (secondary outcomes) with three acute-phase treatments for bipolar II depression. METHOD: In a 16-week, double-blind, multisite comparison study, 142 participants with bipolar II depression were randomly assigned to receive lithium monotherapy (N=49), sertraline monotherapy (N=45), or combination treatment with lithium and sertraline (N=48). At each visit, mood was assessed using standardized rating scales. Rates of switch were compared, as were rates of treatment response and the presence and severity of treatment-emergent side effects. RESULTS: Twenty participants (14%) experienced a switch during the study period (hypomania, N=17; severe hypomania, N=3). Switch rates did not differ among the three treatment groups, even after accounting for dropout. No patient had a manic switch or was hospitalized for a switch. Most switches occurred within the first 5 weeks of treatment. The treatment response rate for the overall sample was 62.7% (N=89), without significant differences between groups after accounting for dropout. The lithium/sertraline combination group had a significantly higher overall dropout rate than the monotherapy groups but did not have an accelerated time to response. CONCLUSIONS: Lithium monotherapy, sertraline monotherapy, and lithium/sertraline combination therapy were associated with similar switch and treatment response rates in participants with bipolar II depression. The dropout rate was higher in the lithium/sertraline combination treatment group, without any treatment acceleration advantage.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Altshuler LL, Sugar CA, McElroy SL, et al. Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison. Am J Psychiatry. 2017. PMID: 28135846. doi:10.1176/appi.ajp.2016.15040558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。